198 related articles for article (PubMed ID: 33456500)
1. External validation of two prediction tools for patients at risk for recurrent
van Rossen TM; van Dijk LJ; Heymans MW; Dekkers OM; Vandenbroucke-Grauls CMJE; van Beurden YH
Therap Adv Gastroenterol; 2021; 14():1756284820977385. PubMed ID: 33456500
[TBL] [Abstract][Full Text] [Related]
2. Healthcare resource utilization and direct medical costs associated with index and recurrent
Feuerstadt P; Stong L; Dahdal DN; Sacks N; Lang K; Nelson WW
J Med Econ; 2020 Jun; 23(6):603-609. PubMed ID: 31999199
[No Abstract] [Full Text] [Related]
3. Prognostic factors for severe and recurrent Clostridioides difficile infection: a systematic review.
van Rossen TM; Ooijevaar RE; Vandenbroucke-Grauls CMJE; Dekkers OM; Kuijper EJ; Keller JJ; van Prehn J
Clin Microbiol Infect; 2022 Mar; 28(3):321-331. PubMed ID: 34655745
[TBL] [Abstract][Full Text] [Related]
4. An Observational Cohort Study of
Rao K; Higgins PDR; Young VB
mSphere; 2018; 3(3):. PubMed ID: 29794054
[TBL] [Abstract][Full Text] [Related]
5. Characterization and risk factors for recurrence of Clostridioides (Clostridium) difficile infection in Japan: A nationwide real-world analysis using a large hospital-based administrative dataset.
Kimura T; Snijder R; Sugitani T
J Infect Chemother; 2019 Aug; 25(8):615-620. PubMed ID: 30987950
[TBL] [Abstract][Full Text] [Related]
6. Validation of clinical risk tools for recurrent
Boone RH; Lee E; Petri WA; Madden GR
Infect Control Hosp Epidemiol; 2024 May; ():1-9. PubMed ID: 38721755
[TBL] [Abstract][Full Text] [Related]
7. Risk factors for recurrent Clostridium difficile infection (CDI) hospitalization among hospitalized patients with an initial CDI episode: a retrospective cohort study.
Zilberberg MD; Reske K; Olsen M; Yan Y; Dubberke ER
BMC Infect Dis; 2014 Jun; 14():306. PubMed ID: 24898123
[TBL] [Abstract][Full Text] [Related]
8. Clinical burden of recurrent
Feuerstadt P; Nelson WW; Teigland C; Dahdal DN
Antimicrob Steward Healthc Epidemiol; 2022; 2(1):e60. PubMed ID: 36483433
[TBL] [Abstract][Full Text] [Related]
9. Incidence and risk factors for recurrent
Baldassarre L; Quach-Thanh C; Mouajou Feujio V; Tadount F; Deyirmendjian C; Lefebvre MA; Thampi N; Schneider O; Fabri-Karam I; O'Donnell S; Okeny-Owere J; Audy N; Desmarais N
Infect Control Hosp Epidemiol; 2024 Feb; 45(2):182-187. PubMed ID: 37700539
[TBL] [Abstract][Full Text] [Related]
10. Development and validation of a recurrent Clostridium difficile risk-prediction model.
Zilberberg MD; Reske K; Olsen M; Yan Y; Dubberke ER
J Hosp Med; 2014 Jul; 9(7):418-23. PubMed ID: 24700708
[TBL] [Abstract][Full Text] [Related]
11. Incidence of and risk factors for recurrent Clostridioidesdifficile infection in Japan using a claims database: A retrospective cohort study.
Mikamo H; Kondo T; Okuyama K; Marcella SW; Ruzicka DJ
Anaerobe; 2020 Feb; 61():102139. PubMed ID: 31830597
[TBL] [Abstract][Full Text] [Related]
12. Trends in and Risk Factors for Recurrent Clostridioides difficile Infection, New Haven County, Connecticut, USA, 2015-2020.
Okafor CM; Clogher P; Olson D; Niccolai L; Hadler J
Emerg Infect Dis; 2023 May; 29(5):877-87. PubMed ID: 37081745
[TBL] [Abstract][Full Text] [Related]
13. Predictors and burden of hospital readmission with recurrent Clostridioides difficile infection: a French nation-wide inception cohort study.
Dinh A; Le Monnier A; Emery C; Alami S; Torreton É; Duburcq A; Barbier F
Eur J Clin Microbiol Infect Dis; 2019 Jul; 38(7):1297-1305. PubMed ID: 30941532
[TBL] [Abstract][Full Text] [Related]
14. Real-world Experience of Bezlotoxumab for Prevention of
Hengel RL; Ritter TE; Nathan RV; Van Anglen LJ; Schroeder CP; Dillon RJ; Marcella SW; Garey KW
Open Forum Infect Dis; 2020 Apr; 7(4):ofaa097. PubMed ID: 32363211
[TBL] [Abstract][Full Text] [Related]
15. Healthcare burden of recurrent Clostridioides difficile infection in Japan: A retrospective database study.
Kunishima H; Ito K; Laurent T; Abe M
J Infect Chemother; 2018 Nov; 24(11):892-901. PubMed ID: 30190105
[TBL] [Abstract][Full Text] [Related]
16. Oral Vancomycin Prophylaxis as Secondary Prevention Against Clostridioides difficile Infection in the Hematopoietic Stem Cell Transplantation and Hematologic Malignancy Population.
Morrisette T; Van Matre AG; Miller MA; Mueller SW; Bajrovic V; Abidi MZ; Benamu E; Kaiser JN; Barber GR; Chase S; Tobin J; Fish DN; Gutman JA
Biol Blood Marrow Transplant; 2019 Oct; 25(10):2091-2097. PubMed ID: 31255741
[TBL] [Abstract][Full Text] [Related]
17. Risk factors for recurrent Clostridium difficile infection in hematopoietic stem cell transplant recipients.
Huang AM; Marini BL; Frame D; Aronoff DM; Nagel JL
Transpl Infect Dis; 2014 Oct; 16(5):744-50. PubMed ID: 25040545
[TBL] [Abstract][Full Text] [Related]
18. Prevention of recurrent Clostridioides difficile infection: A systematic review of randomized controlled trials.
Madoff SE; Urquiaga M; Alonso CD; Kelly CP
Anaerobe; 2020 Feb; 61():102098. PubMed ID: 31493500
[TBL] [Abstract][Full Text] [Related]
19. External Validation of Three Prediction Tools for Patients at Risk of a Complicated Course of Clostridium difficile Infection: Disappointing in an Outbreak Setting.
van Beurden YH; Hensgens MPM; Dekkers OM; Le Cessie S; Mulder CJJ; Vandenbroucke-Grauls CMJE
Infect Control Hosp Epidemiol; 2017 Aug; 38(8):897-905. PubMed ID: 28592343
[TBL] [Abstract][Full Text] [Related]
20. Economic Impact of Recurrent Clostridioides difficile Infection in the USA: A Systematic Literature Review and Cost Synthesis.
Reveles KR; Yang M; Garcia-Horton V; Edwards ML; Guo A; Lodise T; Bochan M; Tillotson G; Dubberke ER
Adv Ther; 2023 Jul; 40(7):3104-3134. PubMed ID: 37210680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
